Evaluation of asymmetric dimethylarginine (ADMA) levels in children with growth hormone deficiency

JCRPE Journal of Clinical Research in Pediatric Endocrinology

Volumn 6, Issue 1, 2014, Pages 22-27

  Önder, Aşan ^a   Aycan, Zehra ^a   Koca, Cemile ^b   Ergin, Merve ^b   Çetinkaya, Semra ^a   Aǧladioǧlu, Sebahat Yilmaz ^a   Kendirci, Havva Nur Peltek ^a   Baş, Veysel Nijat ^a  

^a Dr Sami Ulus Obstetrics and Gynecology   (Turkey)

^b ATATURK TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Asymmetric dimethylarginine; Child; Growth hormone

Indexed keywords

GLUCOSE; GROWTH HORMONE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; INSULIN; LOW DENSITY LIPOPROTEIN; N (G), N (G) DIMETHYLARGININE; SOMATOMEDIN C RECEPTOR; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADOLESCENT; ANTHROPOMETRY; ARTICLE; BODY HEIGHT; BODY WEIGHT; CHEMILUMINESCENCE IMMUNOASSAY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GROWTH HORMONE DEFICIENCY; HOMEOSTASIS; HORMONE SUBSTITUTION; HUMAN; INSULIN RESISTANCE; MALE; PEDIATRICS; PREPUBERTY; SCHOOL CHILD; SPECTROPHOTOMETRY;

ADOLESCENT; ARGININE; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CASE-CONTROL STUDIES; CHILD; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; GROWTH DISORDERS; HUMAN GROWTH HORMONE; HUMANS; INSULIN; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; MALE; PROGNOSIS;

EID: 84895467034     PISSN: 13085727     EISSN: 13085735     Source Type: Journal    
DOI: 10.4274/Jcrpe.1182     Document Type: Article

References (22)

1. Böger RH. Asymmetric dimethylarginine (ADMA) and cardiovascular disease: insights from prospective clinical trials. Vasc Med 2005;10(Suppl 1):19-25.
2. Landim MB, Casella Filho A, Chagas AC. Asymmetric dimethylarginine (ADMA) and endothelial dysfunction: Implications for atherogenesis. Clinics (Sao Paolo) 2009;64:471-478.
3. Anderssohn M, Schwedhelm E, Lüneburg N, Vasan RS, Böger RH. Asymmetric dimethylarginine as a mediator of vascular dysfunction and a marker of cardiovascular disease and mortality: an intriguing interaction with diabetes mellitus. Diab Vasc Dis Res 2010;7:105-118. Epub 2010 Mar 17
4. Krzyzanowska K, Mittermayer F, Schnack C, Hofer M, Wolzt M, Schernthaner G. Circulating ADMA concentrations are elevated in hypopituitary adults with and without growth hormone deficiency. Eur J Clin Invest 2005;35:208-213.
5. Setola E, Monti LD, Lanzi R, Lucotti P, Losa M, Gatti E, Galluccio E, Oldani M, Fermo I, Giovannelli M, Bosi E, Piatti P. Effects of growth hormone treatment on arginine to asymmetric dimethylarginine ratio and endothelial function in patients with growth hormone deficiency. Metabolism 2008;57:1685-1690.
6. Tain YL, Huang LT. Asymmetric dimethylarginine: clinical applications in pediatric medicine. J Formos Med Assoc 2011;110:70-77.
7. Neyzi O, Furman A, Bundak R, Gunoz H, Darendeliler F, Bas F. Growth references for Turkish children aged 6 to 18 years. Acta Paediatr 2006;95:1635-1641.
8. Marshall WA, Tanner JM. Variations in pattern of pubertal changes in girls. Arch Dis Child 1969;44:291-303.
9. Wongwananuruk, T., Rattanachaiyanont, M., Leerasiri, P., et al. (2012) The usefulness of homeostatic measurement assessment-insulin Resistance (HOMA-IR) for detection of glucose intolerance in Thai women of reproductive age with polycystic ovary syndrome. Int J Endocrinol 2012;2012:571035.
10. Haney EM, Huffman LH, Bougatos C, Freeman M, Fu R, Steiner RD, Helfand M, Nelson HD. Screening for lipid disorders in children and adolescents [Internet]. U.S. Preventive Services Task Force Evidence Syntheses, formerly Systematic Evidence Reviews. Editors Rockville (MD): Agency for Healthcare Research and Quality (US); 2007 Jul. Report No: 07-0598-EF-1.
11. Elmlinger MW, Kühnel W, Weber MM, Ranke MB. Reference ranges for two automated chemiluminescent assays for serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 (IGFBP-3). Clin Chem Lab Med 2004;42:654-664.
12. Böger RH, Maas R, Schulze F, Schwedhelm E. Asymmetric dimethylarginine (ADMA) as a prospective marker of cardiovascular disease and mortality--an update on patient populations with a wide range of cardiovascular risk. Pharmacol Res 2009;60:481-487. Epub 2009 Jul 22
13. Verhelst J, Abs R. Cardiovascular risk factors in hypopituitary GH-deficient adults. Eur J Endocrinol 2009;161(Suppl 1):41-49. Epub 2009 Aug 14
14. Thum T, Fleissner F, Klink I, Tsikas D, Jakob M, Bauersachs J, Stichtenoth DO. Growth hormone treatment improves markers of systemic nitric oxide bioavailability via insulin-like growth factor-I. J Clin Endocrinol Metab 2007;92:4172-4179. Epub 2007 Aug 28
15. Ayer JG, Harmer JA, Nakhla S, Xuan W, Ng MK, Raitakari OT, Marks GB, Celermajer DS. HDL-cholesterol, blood pressure and asymmetric dimethylarginine are significantly associated with arterial wall thickness in children. Arterioscler Thromb Vasc Biol 2009;29:943-949. Epub 2009 Apr 9
16. Gruber HJ, Mayer C, Meinitzer A, Almer G, Horejsi R, Möller R, Pilz S, März W, Gasser R, Truschnig-Wilders M, Mangge H. Asymmetric dimethylarginine (ADMA) is tightly correlated with growth in juveniles without correlations to obesity related disorders. Exp Clin Endocrinol Diabetes 2008;116:520-524. Epub 2008 Apr 1
17. Wilcken DE, Sim AS, Wang J, Wang XL. Asymmetric dimethylarginine (ADMA) in vascular, renal and hepatic disease and the regulatory role of L-arginine on its metabolism. Mol Genet Metab 2007;91:309-317. Epub 2007 Jun 7
18. Arrigoni F, Ahmetaj B, Leiper J. The biology and therapeutic potential of the DDAH/ADMA pathway. Curr Phar Des 2010;16:4089-4102.
19. Teerlink T, Luo Z, Palm F, Wilcox CS. Cellular ADMA: regulation and action. Pharmacol Res 2009;60:448-460. Epub 2009 Aug 12
20. Hasanoǧlu A, Okur I, Oren AC, Biberoǧlu G, Oktar S, Eminoǧlu FT, Tümer L. The levels of asymmetric dimethylarginine, homocysteine and carotid intima-media thickness in hypercholesterolemic children. Turk J Pediatr 2011;53:522-527.
21. Jehlicka P, Stozický F, Mayer O Jr, Varvarovská J, Racek J, Trefil L, Siala K. Asymmetric dimethylarginine and the effect of folate substitution in children with familial hypercholesterolemia and diabetes mellitus type 1. Physiol Res 2009;58:179-184. Epub 2008 Apr 1
22. Huemer M, Simma B, Mayr D, Mühl A, Rami B, Schober E, Ulmer H, Zanier U, Bodamer OA. Low levels of asymmetric dimethylarginine in children with diabetes mellitus type I compared with healthy children. J Pediatr 2011;158:602-606. Epub 2010 Nov 12